Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease.

ClinicalTrials.gov ID: NCT00036218

Public ClinicalTrials.gov record NCT00036218. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 3:28 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III, Double-Blind, Placebo-Controlled, Randomized Study Comparing the Efficacy, Safety, and Tolerability of Sumanirole Versus Placebo or Ropinirole in Patients With Early Parkinson's Disease.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary purpose of this study is to determine whether sumanirole is effective and safe in the treatment of the signs and symptoms of early Parkinson's disease.

Study identification

NCT ID
NCT00036218
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Pfizer
Industry
Enrollment
600 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
30 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 2001 (Type not available)
Primary completion
Not listed
Completion
Apr 2003 (Type not available)
Last update posted
Jun 7, 2006

2001 – 2003

United States locations

U.S. sites
93
U.S. states
30
U.S. cities
84
Facility City State ZIP Site status
Pfizer Investigational Site Hot Springs Arkansas 71913 —
Pfizer Investigational Site Little Rock Arkansas 72205 —
Pfizer Investigational Site Carmichael California 95608 —
Pfizer Investigational Site Fresno California 93710 —
Pfizer Investigational Site Irvine California 92618 —
Pfizer Investigational Site La Jolla California 92037 —
Pfizer Investigational Site Loma Linda California 92354 —
Pfizer Investigational Site Los Angeles California 90033 —
Pfizer Investigational Site Oceanside California 92056 —
Pfizer Investigational Site San Francisco California 94109 —
Pfizer Investigational Site San Francisco California 94143 —
Pfizer Investigational Site San Luis Obiapo California 93401 —
Pfizer Investigational Site Walnut Creek California 94596 —
Pfizer Investigational Site Walnut Creek California 94598 —
Pfizer Investigational Site Denver Colorado 80218 —
Pfizer Investigational Site Fairfield Connecticut 06824 —
Pfizer Investigational Site New Haven Connecticut 06510 —
Pfizer Investigational Site Wilmington Delaware 19806 —
Pfizer Investigational Site Boca Raton Florida 33486 —
Pfizer Investigational Site Clearwater Florida 33761 —
Pfizer Investigational Site Fort Lauderdale Florida 33308 —
Pfizer Investigational Site Jacksonville Florida 32209 —
Pfizer Investigational Site Jacksonville Florida 32216 —
Pfizer Investigational Site Maitland Florida 32751 —
Pfizer Investigational Site Miami Florida 33136 —
Pfizer Investigational Site Naples Florida 34102 —
Pfizer Investigational Site Orlando Florida 32806 —
Pfizer Investigational Site Palm Beach Gardens Florida 33410 —
Pfizer Investigational Site Plantation Florida 33324 —
Pfizer Investigational Site St. Petersburg Florida 33703 —
Pfizer Investigational Site Tallahassee Florida 32308 —
Pfizer Investigational Site Tampa Florida 33614 —
Pfizer Investigational Site Atlanta Georgia 30303 —
Pfizer Investigational Site Conyers Georgia 30013 —
Pfizer Investigational Site Decatur Georgia 30033 —
Pfizer Investigational Site Savannah Georgia 31416 —
Pfizer Investigational Site Chicago Illinois 60610 —
Pfizer Investigational Site Chicago Illinois 60612 —
Pfizer Investigational Site Glenbrook Illinois 60025 —
Pfizer Investigational Site Kansas City Kansas 66160 —
Pfizer Investigational Site Lake Charles Louisiana 70601 —
Pfizer Investigational Site Shreveport Louisiana 71135 —
Pfizer Investigational Site Baltimore Maryland 21201 —
Pfizer Investigational Site Columbia Maryland 21044 —
Pfizer Investigational Site Frederick Maryland 21702 —
Pfizer Investigational Site Rockville Maryland 20850 —
Pfizer Investigational Site Boston Massachusetts 02115 —
Pfizer Investigational Site Boston Massachusetts 02118 —
Pfizer Investigational Site Ann Arbor Michigan 48104 —
Pfizer Investigational Site East Lansing Michigan 48848 —
Pfizer Investigational Site Grand Rapids Michigan 49525 —
Pfizer Investigational Site Southfield Michigan 48034 —
Pfizer Investigational Site Traverse City Michigan 49684 —
Pfizer Investigational Site Golden Valley Minnesota 55422 —
Pfizer Investigational Site Minneapolis Minnesota 55455 —
Pfizer Investigational Site Saint Cloud Minnesota 56303 —
Pfizer Investigational Site Kansas City Missouri 64108 —
Pfizer Investigational Site Springfield Missouri 65807 —
Pfizer Investigational Site Omaha Nebraska 68105 —
Pfizer Investigational Site Omaha Nebraska 68131-2197 —
Pfizer Investigational Site Henderson Nevada 89052 —
Pfizer Investigational Site Lebanon New Hampshire 03766 —
Pfizer Investigational Site Morristown New Jersey 07960 —
Pfizer Investigational Site New Brunswick New Jersey 08901 —
Pfizer Investigational Site Ridgewood New Jersey 07450 —
Pfizer Investigational Site Manhasset New York 11030 —
Pfizer Investigational Site Mineola New York 11501 —
Pfizer Investigational Site Mount Vernon New York 10550 —
Pfizer Investigational Site New York New York 10010 —
Pfizer Investigational Site New York New York 10029-6501 —
Pfizer Investigational Site New York New York 10032 —
Pfizer Investigational Site Syracuse New York 13210 —
Pfizer Investigational Site Asheville North Carolina 28803 —
Pfizer Investigational Site Raleigh North Carolina 27607-6520 —
Pfizer Investigational Site Oklahoma City Oklahoma 73104 —
Pfizer Investigational Site Oklahoma City Oklahoma 73118 —
Pfizer Investigational Site Norristown Pennsylvania 19401-3434 —
Pfizer Investigational Site Sellersville Pennsylvania 18960 —
Pfizer Investigational Site Upland Pennsylvania 19013-3995 —
Pfizer Investigational Site Knoxville Tennessee 37916 —
Pfizer Investigational Site Memphis Tennessee 38163 —
Pfizer Investigational Site Nashville Tennessee 37212-3375 —
Pfizer Investigational Site Austin Texas 78756 —
Pfizer Investigational Site Dallas Texas 75390 —
Pfizer Investigational Site Houston Texas 77030 —
Pfizer Investigational Site San Antonio Texas 78229 —
Pfizer Investigational Site Salt Lake City Utah 84107 —
Pfizer Investigational Site Burlington Vermont 05401 —
Pfizer Investigational Site Richmond Virginia 23294 —
Pfizer Investigational Site Bellevue Washington 98004 —
Pfizer Investigational Site Spokane Washington 99204 —
Pfizer Investigational Site Wenatchee Washington 98801 —
Pfizer Investigational Site Milwaukee Wisconsin 53201 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 9 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00036218, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 7, 2006 · Synced Nov 7, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00036218 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →